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Effectiveness of Aneurysm Sac Embolization for Type Ia Endoleak After Endovascular Aneurysm Repair
Elena Marchiori, 1 Giovanni Torsello, 1 Nani Osada, 1 Martin Austermann, 2 Arne Schwindt, 2 Objectives: The best-established strategies to treat type Ia endoleak after endovascular aneurysm repair (EVAR) are either increasing wall apposition of the endograft or extending the landing zone with extension cuffs, fenestrated cuffs, and chimney endografting. However, some patients are not suitable for such methods or present recurrence after those procedures. Aim of this study was to evaluate the effectiveness of embolization to treat type Ia endoleak post-EVAR in highly selected patients.
Methods: Between February 2011 and December 2016, 22 consecutive patients not eligible for either open surgery or complex endovascular repair underwent embolization of a type Ia endoleak post-EVAR at our institution. Society for Vascular Surgery Score was preoperatively performed to assess comorbidity severity. Primary end point was technical success, defined as the absence of type Ia endoleak in the completion angiography. Secondary end points were freedom from aneurysm-related reinterventions and freedom from sac enlargement.
Results: Five patients (22.7%) were symptomatic and four (18.2%) were admitted with a contained rupture of the aneurysm. Mean Society for Vascular Surgery Score was 8.1 6 2.6 (range, 4.0-12.0). The embolization of the endoleak was performed with liquid embolic agent in 12 patients (54.6%), with liquid embolic agent combined with coils and/or plugs in 5 patients (22.7%), and with coils and/or plugs in 5 patients (22.7%). Technical success at the completion angiography was 100%. The postoperative imaging revealed complete sealing of the aneurysm in 14 cases (63.6%). Reintervention-free survival rates at 6 and 12 months were 79.1% and 64.4%, respectively. Ten of 22 patients underwent follow-up by magnetic resonance or computed tomography scans. Freedom from sac enlargement was achieved in six (60%) of 10 patients at a mean follow-up of 14.2 months (range 2.5-33.5 months). Among four patients (40%) with sac enlargement, 1 was treated with fenestrated cuff, 2 were managed expectantly by planning a sac size control in 6 months, and 1 underwent an unsuccessful re-embolization procedure. Objectives: The aim of this study was to measure the intra-aneurysm sac pressure (IASP) and systemic blood pressure (SBP) simultaneously during endovascular aneurysm repair (EVAR) and investigate how IASP depression compared to SBP concerned with the incidence of subsequent type II endoleak (T2E) and the shrinkage of an abdominal aortic aneurysm (AAA) sac diameter after EVAR.
Methods: Between April 2014 and September 2015, 26 patients who underwent EVAR using one of two kinds of stent grafts (Endurant, 18; and Excluder, 8) for an atherosclerotic AAA were reviewed. IASP was measured using the KMP catheter through the 5F introducer placed on the contralateral side of the femoral artery. SBP was measured through either side of the radial artery simultaneously. Completion aortogram showed no type I or type III leaks in all cases. The incidence of T2E at 7 days, 6, and 12 months and AAA sac diameter at 6 and 12 months after EVAR were evaluated by enhanced computed tomography.
Results: IASP (76 6 15 mm Hg) was significantly lowered after EVAR compared to SBP (96 6 14 mm Hg) in all cases (P < .001). The average difference between SBP and IASP (D) was 21 6 14 mm Hg. The D value was 16 6 11 mm Hg, 32 6 14 mm Hg in Endurant cases and Excluder cases, respectively, and they were significantly different (P ¼ .012). On the other hand, there was no correlation between the D value and T2E or aneurysmal sac shrinkage after EVAR statistically.
Conclusions: IASP was reduced by EVAR using Endurant and Excluder. Excluder significantly reduced IASP compared to Endurant.
However those D values did not concern with T2E or aneurysmal sac shrinkage after EVAR. To reduce T2E or achieve aneurysmal sac shrinkage, alternative methods should be considered, such as embolization of T2E sources during EVAR or severe postoperative blood pressure control.
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Evaluation of PEVAR Therapeutic Benefits in a Large Single-Center Experience Results: During the study period, 236 cases were analyzed. Among these patients, 137 patients underwent PEVAR, and 99 patients underwent SEVAR. There were no significant differences in demographics between PEVAR and SEVAR groups (Table I) . PEVAR patients had a shorter hospital length of stay, operation time, intensive care unit time, and lower frequency of total access site complications (hematoma, pseudoaneurysm, lymphocele, infection, or dissection). Moreover, PEVAR did not increase the risk of postoperative complications, readmissions, or reoperations (Table II) .
Conclusions: In a large reported PEVAR patient group, we observed that PEVAR was a safe alternative to SEVAR. Most notably, patients who underwent PEVAR had shorter operative times, reduced hospital stay, and less access site complications. 
